PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers

NCT07256600 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-12-03

No results posted yet for this study

Summary

A bioequivalence study comparing DWJ1445 and DWC202506 in healthy adults

Conditions

  • Healthy Subjects

Interventions

DRUG

DWJ1445

1 tablet, Orally

DRUG

DWC202506

1 tablet, Orally

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-14
Primary Completion
2025-11-23
Completion
2025-12-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07256600 on ClinicalTrials.gov